CD20-γδ T cell therapy / LinXCell Biotechnologies - LARVOL DELTA

A novel CD20-conjugated γδ T cell therapy via unnatural sugar-mediated chemical modification for the treatment of EBV-PTLD (ASH 2025) - "In vitro, the CD20antibody-conjugated γδ T (CD20-γδ T) cells were co-cultured with EBV and CD20-positive targets,including EBV-transformed lymphoblastoid cell lines (EBV-LCLs), Raji cells, rituximab-resistant Raji cells,and primary EBV-PTLD patient-derived cells... We developed a novel off-the-shelf CD20-γδ T cell therapy using MGL-based ACCtechnology, effectively combining the innate antitumor activity of γδ T cells with the precision of CD20targeting. This approach exhibits potent efficacy against EBV-PTLD in vitro and in vivo, offering apromising allogeneic immunotherapy for refractory EBV-associated diseases."

Epstein-Barr Virus Infections • Solid Organ Transplantation • CD20